首页> 外文期刊>BMC Infectious Diseases >Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia: a prospective observational study
【24h】

Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia: a prospective observational study

机译:痰革兰氏染色在治疗社区获得性肺炎和医疗保健相关性肺炎中的有效性:一项前瞻性观察研究

获取原文
           

摘要

Background The usefulness of sputum Gram stain in patients with community-acquired pneumonia (CAP) is controversial. There has been no study to evaluate the diagnostic value of this method in patients with healthcare-associated pneumonia (HCAP). The purpose of this study was to evaluate the usefulness of sputum Gram stain in etiological diagnosis and pathogen-targeted antibiotic treatment of CAP and HCAP. Methods We conducted a prospective observational study on hospitalized patients with pneumonia admitted to our hospital from August 2010 to July 2012. Before administering antibiotics on admission, Gram stain was performed and examined by trained physicians immediately after sputum samples were obtained. We analyzed the quality of sputum samples and the diagnostic performance of Gram stain. We also compared pathogen-targeted antibiotic treatment guided by sputum Gram stain with empirical treatment. Results Of 670 patients with pneumonia, 328 were CAP and 342 were HCAP. Sputum samples were obtained from 591 patients, of these 478 samples were good quality. The sensitivity and specificity of sputum Gram stain were 62.5% and 91.5% for Streptococcus pneumoniae, 60.9% and 95.1% for Haemophilus influenzae, 68.2% and 96.1% for Moraxella catarrhalis, 39.5% and 98.2% for Klebsiella pneumoniae, 22.2% and 99.8% for Pseudomonas aeruginosa, 9.1% and 100% for Staphylococcus aureus. The diagnostic yield decreased in patients who had received antibiotics or patients with suspected aspiration pneumonia. Pathogen-targeted treatment provided similar efficacy with a decrease in adverse events compared to empirical treatment. Conclusions Sputum Gram stain is highly specific for the etiologic diagnosis and useful in guiding pathogen-targeted antibiotic treatment of CAP and HCAP.
机译:背景痰液革兰氏染色在社区获得性肺炎(CAP)患者中的有用性存在争议。尚无研究评估此方法对医疗保健相关性肺炎(HCAP)患者的诊断价值。这项研究的目的是评估痰革兰氏染色在CAP和HCAP的病原学诊断和针对病原体的抗生素治疗中的实用性。方法我们对2010年8月至2012年7月住院的肺炎住院患者进行了一项前瞻性观察研究。入院前对抗生素进行革兰氏染色并在获得痰标本后立即由经过培训的医生进行检查。我们分析了痰标本的质量和革兰氏染色的诊断性能。我们还将痰革兰氏染色指导的针对病原体的抗生素治疗与经验治疗进行了比较。结果670例肺炎患者中,CAP 328例,HCAP 342例。从591位患者中获得了痰标本,其中478份标本质量良好。痰革兰氏染色对肺炎链球菌的敏感性和特异性分别为62.5%和91.5%,流感嗜血杆菌为60.9%和95.1%,卡他莫拉菌为68.2%和96.1%,肺炎克雷伯菌为39.5%和98.2%,肺炎克雷伯菌为22.2%和99.8%。对于铜绿假单胞菌,金黄色葡萄球菌为9.1%和100%。接受抗生素治疗的患者或疑似吸入性肺炎的患者诊断率下降。与经验治疗相比,针对病原体的治疗提供了相似的功效,且不良事件有所减少。结论痰革兰氏染色对病原学诊断具有很高的特异性,可用于指导针对CAP和HCAP的病原体靶向抗生素治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号